Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions
Zhibin Chen, Danny Liew, Patrick Kwan
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
OBJECTIVE: To assess the effects of an active pharmacogenetic screening policy for antiepileptic drug (AED) therapy on everyday clinical practice and clinical outcomes. METHODS: We extracted data covering all public hospitals and clinics in Hong Kong for patients who were newly commenced on carbamazepine or other AEDs, or were tested for HLA-B*15:02 3 years before policy implementation (prepolicy: September 16, 2005 to September 15, 2008) and 3 years after (postpolicy: September 16, 2008 to September 15, 2011). We compared AED prescriptions and the incidence of SJS/TEN between the 2 periods and analyzed adherence to the policy. RESULTS: A total of 111,242 patients were included and 4,149 wer..View full abstract
Z. Chen reports no disclosures. D. Liew has received research grants from the National Health and Medical Research Council of Australia, the Australian Research Council, and the National Heart Foundation of Australia. He/his institution has also received speaker or consultancy fees and/or research grants from Pfizer, AbbVie, Sanofi, AstraZeneca, GlaxoSmithKline, and Amgen. P. Kwan has received research grants from the National Health and Medical Research Council of Australia, the Australian Research Council, the US NIH, Hong Kong Research Grants Council, Innovation and Technology Fund, Health and Health Services Research Fund, and Health and Medical Research Fund. He/his institution also received speaker or consultancy fees and/or research grants from Eisai, GlaxoSmithKline, Johnson & Johnson, Pfizer, and UCB Pharma. Go to Neurology.org for full disclosures.